Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis

Saeed Khoshnood; Elahe Taki; Nourkhoda Sadeghifard; Vahab Hassan Kaviar; Mohammad Hossein Haddadi; Zahra Farshadzadeh; Zahra Farshadzadeh; Ebrahim Kouhsari; Mehdi Goudarzi; Mohsen Heidary; Mohsen Heidary

doi:10.3389/fmicb.2021.717045

Frontiers in Microbiology (Oct 2021)

Mechanism of Action, Resistance, Synergism, and Clinical Implications of Delamanid Against Multidrug-Resistant Mycobacterium tuberculosis

Saeed Khoshnood,
Elahe Taki,
Nourkhoda Sadeghifard,
Vahab Hassan Kaviar,
Mohammad Hossein Haddadi,
Zahra Farshadzadeh,
Zahra Farshadzadeh,
Ebrahim Kouhsari,
Mehdi Goudarzi,
Mohsen Heidary,
Mohsen Heidary

Affiliations

Saeed Khoshnood: Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
Elahe Taki: Department of Microbiology, School of Medicine, Tehran University of Medical Sciences, Tehran, Iran
Nourkhoda Sadeghifard: Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
Vahab Hassan Kaviar: Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
Mohammad Hossein Haddadi: Clinical Microbiology Research Center, Ilam University of Medical Sciences, Ilam, Iran
Zahra Farshadzadeh: Infectious and Tropical Diseases Research Center, Health Research Institute, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Zahra Farshadzadeh: Department of Microbiology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
Ebrahim Kouhsari: Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran
Mehdi Goudarzi: Department of Microbiology, School of Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran
Mohsen Heidary: Department of Laboratory Sciences, School of Paramedical Sciences, Sabzevar University of Medical Sciences, Sabzevar, Iran
Mohsen Heidary: Cellular and Molecular Research Center, Sabzevar University of Medical Sciences, Sabzevar, Iran

DOI: https://doi.org/10.3389/fmicb.2021.717045
Journal volume & issue: Vol. 12

Abstract

Read online

Multidrug-resistant (MDR) isolates of Mycobacterium tuberculosis (MTB) remain a primary global threat to the end of tuberculosis (TB) era. Delamanid (DLM) is a nitro-dihydro-imidazooxazole derivative utilized to treat MDR-TB. DLM has distinct mechanism of action, inhibiting methoxy- and keto-mycolic acid (MA) synthesis through the F420 coenzyme mycobacteria system and generating nitrous oxide. While DLM resistance among MTB strains is uncommon, there are increasing reports in Asia and Europe, and such resistance will prolong the treatment courses of patients infected with MDR-TB. In this review, we address the antimycobacterial properties of DLM, report the global prevalence of DLM resistance, discuss the synergism of DLM with other anti-TB drugs, and evaluate the documented clinical trials to provide new insights into the clinical use of this antibiotic.

Published in Frontiers in Microbiology

ISSN: 1664-302X (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Science: Microbiology
Website: http://www.frontiersin.org/journals/microbiology

About the journal

Abstract

Keywords